Showing results (351-360 of 554) with videos related to
Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelinesK A Margolin, A A Rayner, M J Hawkins, et al.Blood|November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma productionJ P Leonard, M L Sherman, G L Fisher, et al.Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapiesMichael B Atkins, Paolo A Ascierto, David Feltquate, et al.JAMA Network Open|August 1, 2023
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical TrialAnlan Cao, Brenda Cartmel, Fang-Yong Li, et al.JNCI Cancer Spectrum|July 31, 2018
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for ManagementMonica Girotra, Aaron Hansen, Azeez Farooki, et al.Journal of Clinical Immunology|November 1, 1988
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJ W Mier, G Vachino, J W van der Meer, et al.The Oncologist|January 23, 2024
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 TrialKathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation StudyMargaret K Callahan, Harriet Kluger, Michael A Postow, et al.The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.British Journal of Cancer|June 16, 2011
Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinomaR S Bhatt, A J Zurita, A O'Neill, et al.Pageof 56